Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00387686
Status:
TERMINATED
Last Update Posted:
2013-02-28
First Post:
2006-10-11
Brief Title:
A Phase 23 Multicenter Controlled Trial Of rhBMP-2CPM In Tibial Fractures
Sponsor:
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
367
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: